Product Information
PREGABALIN 225 MG CAPSULE is a generic product labeled by Ascend Laboratories, LLC, priced at $0.0635 per EA under NDC 67877046890. Its NADAC has been published 370 times since Sep 4, 2019.
FDA first approved this application on Jul 19, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
225 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877046890
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PREGABALINApproval Type
Generic (ANDA)
FDA Application
ANDA207799FDA Approved
7/19/2019
TE Code
AB
On Market Since
7/21/2019
Price Statistics
The NADAC for PREGABALIN 225 MG CAPSULE has been published 370 times since Sep 4, 2019, and over the history we have for it it has declined 73.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0635 per EA |
|---|---|
| All-time high | $0.2382 (Sep 11, 2019) |
| All-time low | $0.0529 (Nov 20, 2024) |
| 52-week high | $0.0690 |
| 52-week low | $0.0543 |
| Median price | $0.0892 |
| Average price | $0.1049 |
| Largest weekly change | -29.0% (Nov 20, 2024) |
| Weeks tracked | 370 |
| Tracking since | Sep 4, 2019 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pregabalin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PREGABALIN 225 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PREGABALIN 225 MG CAPSULE, manufactured by Ascend Laboratories, LLC, is $0.0635 per EA (NDC 67877046890), effective Sep 30, 2026.
How has the price of PREGABALIN 225 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PREGABALIN 225 MG CAPSULE has declined 73.3%. It has been tracked across 370 weekly CMS publications since Sep 4, 2019.
What are the highest and lowest recorded NADAC prices for PREGABALIN 225 MG CAPSULE?
Since Sep 4, 2019, the NADAC for PREGABALIN 225 MG CAPSULE has ranged from a low of $0.0529 (Nov 20, 2024) to a high of $0.2382 (Sep 11, 2019), with a median of $0.0892 per EA.
Are there cheaper alternatives to PREGABALIN 225 MG CAPSULE?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PREGABALIN 225 MG CAPSULE, is $0.0609 per EA — about 4% below PREGABALIN 225 MG CAPSULE.
Who manufactures PREGABALIN 225 MG CAPSULE?
PREGABALIN 225 MG CAPSULE (NDC 67877046890) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.